Batool Sania, Chokkakula Santosh, Jeong Ju Hwan, Baek Yun Hee, Song Min-Suk
Department of Microbiology, Chungbuk National University, College of Medicine and Medical Research Institute, Cheongju 28644, Chungbuk, Republic of Korea.
Heliyon. 2025 Jan 15;11(2):e41980. doi: 10.1016/j.heliyon.2025.e41980. eCollection 2025 Jan 30.
In light of the transition of COVID-19 from a pandemic to an endemic phase, there is still a dire need to address challenges associated with drug resistance, particularly among immunocompromised and high-risk populations. This review explores the current state of research on SARS-CoV-2 drug resistance and underscores the ongoing need for effective therapeutic strategies. It critically evaluates existing knowledge on resistance mechanisms and therapeutic options, aiming to consolidate information and highlight areas for future research. By examining the complex interactions between the virus and its host, the review advocates for a multifaceted approach, including combination therapies, targeted drug development, and continuous surveillance of viral mutations. It also emphasizes the impact of evolving viral variants on antiviral efficacy and suggests adaptive treatment protocols. This review aims to enhance our understanding of SARS-CoV-2 drug resistance and contribute to more effective management of COVID-19 through a discussion of promising strategies such as drug repurposing and combination therapies.
鉴于新冠病毒已从大流行阶段过渡到地方流行阶段,仍然迫切需要应对与耐药性相关的挑战,尤其是在免疫功能低下和高危人群中。本综述探讨了新冠病毒耐药性的研究现状,并强调了对有效治疗策略的持续需求。它批判性地评估了关于耐药机制和治疗选择的现有知识,旨在整合信息并突出未来研究的领域。通过研究病毒与其宿主之间的复杂相互作用,本综述提倡采用多方面的方法,包括联合疗法、靶向药物开发以及对病毒突变的持续监测。它还强调了不断演变的病毒变体对抗病毒疗效的影响,并提出了适应性治疗方案。本综述旨在通过讨论药物重新利用和联合疗法等有前景的策略,增强我们对新冠病毒耐药性的理解,并为更有效地管理新冠疫情做出贡献。